Rituximab News and Research

RSS
Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
Southampton researchers find new approach to reverse treatment resistance in lymphoma patients

Southampton researchers find new approach to reverse treatment resistance in lymphoma patients

Adding new antibody to chemotherapy could bolster effects of cancer treatment

Adding new antibody to chemotherapy could bolster effects of cancer treatment

ACR, AAHKS release new guideline to reduce joint infections after total hip and knee replacements

ACR, AAHKS release new guideline to reduce joint infections after total hip and knee replacements

Study finds no clear benefit of stem-cell transplant for double-hit lymphoma patients in remission

Study finds no clear benefit of stem-cell transplant for double-hit lymphoma patients in remission

WHO to launch pilot project for prequalifying biosimilar cancer medicines

WHO to launch pilot project for prequalifying biosimilar cancer medicines

New technique opens door for biochemists to create better therapeutic antibodies

New technique opens door for biochemists to create better therapeutic antibodies

New discovery could lead to development of new cancer treatments

New discovery could lead to development of new cancer treatments

Scientists discover adverse, unpredictable side effects of approved MS therapy

Scientists discover adverse, unpredictable side effects of approved MS therapy

Biologic drugs may help prevent progressive bone loss in patients with RA

Biologic drugs may help prevent progressive bone loss in patients with RA

Nova Southeastern University hosts international conference organized by IACFS/ME

Nova Southeastern University hosts international conference organized by IACFS/ME

Researchers identify higher risk of early chemotherapy-related death in older patients with DLBCL

Researchers identify higher risk of early chemotherapy-related death in older patients with DLBCL

MedUni Vienna scientists aim to identify prognostic markers for cutaneous lymphomas

MedUni Vienna scientists aim to identify prognostic markers for cutaneous lymphomas

Study demonstrates safety and effectiveness of new SLN radiotracer in breast cancer patients

Study demonstrates safety and effectiveness of new SLN radiotracer in breast cancer patients

Neurologists identify cause of immune-mediated neuropathies

Neurologists identify cause of immune-mediated neuropathies

Two new studies find potential genetic cause and new treatment method for autoimmune diseases

Two new studies find potential genetic cause and new treatment method for autoimmune diseases

Added benefit of idelalisib drug not proven for patients with CLL

Added benefit of idelalisib drug not proven for patients with CLL

New strategy treats fatal autoimmune disease without outward off-target effects

New strategy treats fatal autoimmune disease without outward off-target effects

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

Switch to rituximab shows anti-inflammatory effect in relapsing-remitting MS

Switch to rituximab shows anti-inflammatory effect in relapsing-remitting MS

Real risk of rebound syndrome following fingolimod cessation for MS

Real risk of rebound syndrome following fingolimod cessation for MS